Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis

Nephrology

Volumn 18, Issue 10, 2013, Pages 690-699

  Qin, Jiao ^a   Xie, Yan Yun ^a   Huang, Ling ^a   Yuan, Qiong Jing ^a   Mei, Wen Juan ^a   Yuan, Xiang Ning ^a   Hu, Gao Yun ^b   Cheng, Guang Jie ^c   Tao, Li Jian ^a,b   Peng, Zhang Zhe ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c University of Alabama at Birmingham   (United States)

Author keywords

Akt; fluorofenidone; nicotinamide adeninedinucleotide phosphate oxidase; renal interstitial fibrosis

Indexed keywords

ANGIOTENSIN II; ANTIFIBROTIC AGENT; ANTIOXIDANT; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FLUOROFENIDONE; LOSARTAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN F2 ALPHA; PROTEIN KINASE B; PROTEIN P47; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY FIBROSIS; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; URETER OBSTRUCTION;

AKT; FLUOROFENIDONE; NICOTINAMIDE ADENINEDINUCLEOTIDE PHOSPHATE OXIDASE; RENAL INTERSTITIAL FIBROSIS;

ANGIOTENSIN II; ANIMALS; ANTIOXIDANTS; CELL LINE; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; COLLAGEN TYPE I; DINOPROST; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FIBROSIS; KIDNEY DISEASES; KIDNEY TUBULES; LIPID PEROXIDATION; LOSARTAN; MALE; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; OXIDATIVE STRESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRANSFECTION; URETERAL OBSTRUCTION;

EID: 84884847661     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12128     Document Type: Article

References (29)

1. Cho ME, Smith. DC, Branton MH, Penzak SR, Kopp JB,: Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2007; 2: 906-913.
2. Friederich-Persson M, Aslam S, Nordquist L, Welch WJ, Wilcox CS, Palm F,. Acute knockdown of uncoupling protein-2 increases uncoupling via the adenine nucleotide transporter and decreases oxidative stress in diabetic kidneys. PLoS ONE 2012; 7: e39635.
3. Liu CM, Sun. Y, Sun JM, Ma JQ, Cheng C,: Protective role of quercetin against lead-induced inflammatory response in rat kidney through the ROS-mediated MAPKs and NF-κB pathway. Biochim. Biophys. Acta 2012; 1820: 1693-1703.
4. Pozzi AVP, Hudson BG, Zent R,. Regulation of matrix synthesis, remodeling and accumulation in glomerulosclerosis. Curr. Pharm. Des. 2009; 15: 1318-1333.
5. Klahr S, Morrissey L,. Obstructive nephropathy and renal fibrosis. Am. J. Physiol. Renal Physiol. 2002; 283: F861-875.
6. de Borst MH, van Timmeren MM, Vaidya VS, et al. Induction of kidney injury molecule-l in homozygous Ren2 rats is attenuated by blockade of the renin-angiotensin system or p38 MAP kinase. Am. J. Physiol. Renal Physiol. 2007; 292: F313-320.
7. Cheng G, Cao. Z, Xu X, van Meir EG, Lambeth JD,: Homologs of gp91phox: Cloning and tissue expression of Nox3, Nox4 and Nox5. Gene 2001; 269: 131-140.
8. Brandes. RP,: Triggering mitochondrial radical release a new function for NADPH oxidases. Hypertention 2005; 45: 847-848.
9. Peng ZZ, Hu G, Shen H, et al. Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells. Nephrology (Carlton) 2009; 14: 565-572.
10. Kanai F, Liu H, Field SJ, et al. The PX domains of p47phox and p40phox bind to lipid products of PI(3)K. Nat. Cell Biol. 2001; 3: 675-678.
11. Datta SR, Brunet A, Greenberg ME,. 'Cellular survival: A play in three akts. Genes Dev. 1999; 13: 2905-2927.
12. Nakayama S, Mukae H, Sakamoto N, et al. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci. 2008; 82: 210-217.
13. Van Erp C, Irwin NG, Hoey AJ,. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve 2006; 34: 327-334.
14. Di Sario A, Bendia E, Macarri G, et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig. Liver Dis. 2004; 36: 744-751.
15. Webb NJ, Shahinfar S, Wells TG, et al. Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int. 2012; 82: 819-826.
16. Han CJ, Liu J, Li M, et al. Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway. Inflamm. Res. 2012; 61: 1031-1037.
17. Le Tulzo Y, Shenkar R, Kaneko D, et al. Hemorrhage increases cytokine expression in lung mononuclear cells in mice: Involvement of catecholamines in nuclear factor-kappaB regulation and cytokine expression. J. Clin. Invest. 1997; 99: 1516-1524.
18. Yuan Q, Wang L, Zhang F, et al. Fluorofenidone suppresses epithelial-mesenchymal transition and the expression of connective tissue growth factor via inhibiting TGF-beta/Smads signaling in human proximal tubular epithelial cells. Pharmazie 2011; 66: 961-967.
19. Gorin Y, Block K, Hernandez J, et al. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J. Biol. Chem. 2005; 280: 39616-39626.
20. Sugiyama H, Kobayashi M, Wang DH, et al. Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol. Dial. Transplant. 2005; 20: 2670-2680.
21. Chen LX, Yang K, Sun M, et al. Fluorofenidone inhibits transforming growth factor-beta1-induced cardiac myofibroblast differentiation. Pharmazi 2012; 67: 452-456.
22. Meng JZ, Hu C, Zhu Y, et al. Fluorofenidone attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice via restoring caveolin 1 expression and inhibiting mitogen-activated protein kinase signaling pathway. Shock 2012; 38: 567-573.
23. Kawada N, Moriyama T, Ando A, et al. Increased oxidative stress in mouse kidneys with unilateral ureteral obstruction. Kidney Int. 1999; 56: 1004-1013.
24. Chade AR, Rodriguez-Porcel M, Herrmann J, et al. Beneficial effects of antioxidant vitamins on the stenotic kidney. Hypertension 2003; 42: 605-612.
25. Lassegue B, Clempus R,. Vascular NAD(P)H oxidases: Specific features, expression, and regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003; 285: R277-297.
26. Gorin Y, Ricono J, Kim NH, Bhandari B, Choudhury GG, Abboud HE,. Nox4 mediates angiotensin II-induced activation of Akt /protein kinase B in mesangial cells. Am. J. Physiol. Renal Physiol. 2003; 285: F219-229.
27. Cheng G, Diebold B, Hughes Y, Lambeth JD,. Nox1-dependent Reactive Oxygen Generation Is Regulated by Rac1. J. Biol. Chem. 2006; 281: 17 718-726.
28. Zimmerman D, Burns K,. Angiotensin-(1-7) in kidney disease: A review of the controversies. Clin. Sci. (Lond.) 2012; 123: 333-346.
29. Kimura S, Zhang. G, Nishiyama A, et al. Role of NAD(P)H oxidase- and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 2005; 45: 860-866.